

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/T70262E0545CEN.html>

Date: March 2022

Pages: 122

Price: US\$ 3,500.00 (Single User License)

ID: T70262E0545CEN

Abstracts

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 27 molecules are developed by Companies. The latest report GMDHC22029TDB - Tyrosine Protein Kinase SYK - Drugs In Development, 2022, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The

phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 10, 2, 10 and 1 respectively.

Report covers products from therapy areas Oncology, Immunology, Ophthalmology, Dermatology, Hematological Disorders, Respiratory, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Diffuse Large B-Cell Lymphoma, Rheumatoid Arthritis, Allergic Conjunctivitis, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acquired (Autoimmune) Hemolytic Anemia, Asthma, Atopic Dermatitis (Atopic Eczema), Mantle Cell Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Epithelial Ovarian Cancer, Follicular Lymphoma, Kidney Transplant Rejection, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Respiratory Distress Syndrome, Allergies, Alopecia Areata, Alzheimer's Disease, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Fallopian Tube Cancer, Gastric Cancer, Hand Dermatitis, Hidradenitis Suppurativa, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis Sicca (Dry Eye), Ocular Inflammation, Peritoneal Cancer, Psoriasis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified B-Cell Lymphomas, Unspecified Ophthalmological Disorders and Vitiligo.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create

effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AB Science SA

Alexion Pharmaceuticals Inc

Aptose Biosciences Inc

Archer Pharmaceuticals Inc

Asana BioSciences LLC

Beijing Hanmi Pharmaceutical Co Ltd

Calithera Biosciences Inc

Clevexel Pharma SA

CSPC Pharmaceutical Group Ltd

Genosco Inc

GlaxoSmithKline Plc

Hutchison MediPharma Ltd

IACTA Pharmaceuticals Inc

Japan Tobacco Inc

Kronos Bio Inc

Levolta Pharmaceuticals Inc

Nano Biotherapeutics Inc

Origenis GmbH

Pulmatrix Inc

Rigel Pharmaceuticals Inc

Taiho Pharmaceutical Co Ltd

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Drug Profiles

AB-8779 - Drug Profile

Product Description

Mechanism Of Action

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

cevidoplenib - Drug Profile

Product Description

Mechanism Of Action

History of Events

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

History of Events

entospletinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

fostamatinib disodium - Drug Profile

Product Description

Mechanism Of Action

History of Events

GNS-1653 - Drug Profile

Product Description

Mechanism Of Action

GS-492429 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GSK-2646264 - Drug Profile

Product Description

Mechanism Of Action

History of Events

gusacitinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action
History of Events
HM-43239 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-265 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-270 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JTE-852 - Drug Profile
Product Description
Mechanism Of Action
lanraplenib succinate - Drug Profile
Product Description
Mechanism Of Action
History of Events
mivavotinib citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
nilvadipine - Drug Profile
Product Description
Mechanism Of Action
History of Events
piceatannol albumin bound - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PUR-1800 - Drug Profile
Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit SYK and JAK for Rheumatoid Arthritis and Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit SYK for Ocular Inflammation - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit H1-SYK for Unspecified Ophthalmic Diseases - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

sofleplenib - Drug Profile

Product Description

Mechanism Of Action

History of Events

SYHX-1901 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TAS-05567 - Drug Profile

Product Description

Mechanism Of Action

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Mar 08, 2022: Rigel announces publication of data from phase 2 clinical study of

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy A...

fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia in the American Journal of Hematology

Jan 12, 2022: HUTCHMED receives Breakthrough Therapy designation in China for HMPL-523 for treatment of primary immune thrombocytopenia

Dec 21, 2021: Fostamatinib meets primary endpoint in phase 3 trial in Japan for treatment of chronic immune thrombocytopenia

Dec 14, 2021: HUTCHMED highlights HMPL-523 clinical data presented at the 2021 ASH Annual Meeting

Dec 13, 2021: HM43239 demonstrates durable clinical benefit in acute myeloid leukemia

Dec 06, 2021: Kronos Bio announces first patient dosed in AGILITY phase 3 clinical trial of entospletinib in patients with newly diagnosed NPM1-mutated acute myeloid leukemia

Nov 15, 2021: Rigel sharpens focus on its advanced portfolio opportunities

Nov 08, 2021: HUTCHMED highlights HMPL-523 clinical data to be presented at the 2021 ASH Annual Meeting

Oct 27, 2021: HUTCHMED initiates ESLIM-01, a phase III trial of HMPL-523 in patients with immune thrombocytopenia in China

Sep 01, 2021: Data from NIH/NHLBI-sponsored phase 2 trial of Fostamatinib in hospitalized COVID-19 patients published in clinical infectious diseases

Aug 13, 2021: Rigel Pharmaceuticals provides update on COVID-19 program

Jul 27, 2021: Kronos Bio announces FDA clearance of investigational new drug application for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)

Jul 14, 2021: New TAVALISSE data analyses to be presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Jun 29, 2021: Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial

Apr 22, 2021: Asana BioSciences to present additional efficacy data from chronic hand eczema Phase 2b trial of oral SYK/JAK inhibitor Gusacitinib at AAD VMX late-breaking session

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AB Science SA, 2022

Pipeline by Alexion Pharmaceuticals Inc, 2022

Pipeline by Aptose Biosciences Inc, 2022

Pipeline by Archer Pharmaceuticals Inc, 2022

Pipeline by Asana BioSciences LLC, 2022

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, 2022

Pipeline by Calithera Biosciences Inc, 2022

Pipeline by Clevexel Pharma SA, 2022

Pipeline by CSPC Pharmaceutical Group Ltd, 2022

Pipeline by Genosco Inc, 2022

Pipeline by GlaxoSmithKline Plc, 2022

Pipeline by Hutchison MediPharma Ltd, 2022

Pipeline by IACTA Pharmaceuticals Inc, 2022

Pipeline by Japan Tobacco Inc, 2022

Pipeline by Kronos Bio Inc, 2022

Pipeline by Levolta Pharmaceuticals Inc, 2022

Pipeline by Nano Biotherapeutics Inc, 2022

Pipeline by Origenis GmbH, 2022

Pipeline by Pulmatrix Inc, 2022

Pipeline by Rigel Pharmaceuticals Inc, 2022

Pipeline by Taiho Pharmaceutical Co Ltd, 2022

Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

I would like to order

Product name: Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and
Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/T70262E0545CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/T70262E0545CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970